A Phase 1/2 interventional study of Liugan Shuangjie Heji and Shufeng Jiedu Capsule in Influenza, sponsored by Dongfang Hospital Beijing University of Chinese Medicine. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-10-09.
Sponsored by Dongfang Hospital Beijing University of Chinese Medicine · Phase 1/2, Interventional, and Treatment
This prospective randomized controlled trial studies the efficacy and safety of treating influenza with the reconciling exterior and interior therapy. A total of 300 cases of seasonal flu in Beijing is to be collected, and divided into one treatment group and two control groups. Patients in the treatment group will receive Liugan Shuangjie Heji, while patients in control groups will receive Shufeng Jiedu Capsule and Oseltamivir Phosphate Capsule respectively, for a course of 5 days. The study assesses the efficacy and safety of treating influenza with the reconciling therapy based on the following outcome measures: the time it takes from the medicine intake to 0.5℃ drop of body temperature, and the time it takes for the body temperature to return to normal.
2,265 studies on the registry are indexed under Influenza, Human; 173 are open to participants now.
This study's planned enrollment of 300 is above the median of 240 across 1,894 interventional studies indexed under Influenza, Human.
Browse Influenza, Human studies →Dongfang Hospital Beijing University of Chinese Medicine is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
Drug: Liugan Shuangjie Heji
Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
Drug: Shufeng Jiedu Capsule
Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
Drug: Oseltamivir Phosphate Capsule
time from the medicine intake to 0.5℃ drop of body temperature
Time frame: five days
time for the body temperature to return to normal
Time frame: five days
The record gives a start of Nov 2014, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dongfang Hospital Beijing University of Chinese Medicine